Blood Plasma Derivatives Market Research Report - Forecast till 2027

Blood Plasma Derivatives Market Research Report: Information by Type [Factor VIII Concentrate, Factor IX Concentrate, Albumin, Immune Globulins, Anti-Thrombin III Concentrate, and Fresh Frozen Plasma (FFP)], Application (HIV, Hemophilia A, Hemophilia B, Hepatitis B, Hepatitis C, Bleeding Disorders, Hypogammaglobulinemia, Immunodeficiency Diseases, and Others), End User (Hospitals & Clinics, Blood Transfusion Centers, Diagnostic Centers, and Others), and Region (Americas, Europe, Asia-Pacific, and Middle East & Africa)—Forecast till 2027

ID: MRFR/Pharma/0817-HCR | February 2021 | Region: Global | 80 pages

Blood Plasma Derivatives Market Overview


The Blood Plasma Derivatives Market is becoming essential because of the expanding interest for plasma inferred items. As indicated by a new market, The Blood Plasma Derivatives Industry is enhancing its growth and is expected to acquire noticeable quality over the estimated period. The market is estimated to show a breathtaking development by the end of 2023, outperforming its past development records as far as worth with a striking CAGR during the expected period (2017 – 2023). 


You must know that Plasma is a liquid piece of the blood that contains platelets and protein answerable for blood thickening. Plasma Derivatives are obtained from explicit plasma proteins by the cycle of fractionation. The Derivatives are then dissolvable cleansers treated or heat-treated to kill certain infections. The most widely recognized plasma subsidiary mainly includes factor IX concentrate, hostile to inhibitor coagulation complex (AICC), factor VIII concentrate, against thrombin III concentrate, Alpha 1-Proteinase inhibitor concentrate, insusceptible globulins, egg whites, and against thrombin III concentrates. Blood plasma derivatives 3 are broadly utilized clinically to treat different conditions, such as HIV, thrombocytosis, hemophilia A, hemophilia B, hepatitis B, hepatitis C, etc. 


Rising interest in plasma derivatives-based treatments is the key factor driving the blood plasma derivatives market. As per an investigation distributed in the Journal of Plasma Medicine in 2016, it is discovered that FIX substitution treatment, which incorporates plasma-inferred protein, is fruitful in the decrease of incapacity and draining from hemophilia B. Based on the commonness rate, hemophilia and von Willebrand sickness (VWD) are the most widely recognized draining problems in the Middle East & Africa. In recent times the blood plasma derivatives market demand is increasing due to the effective use of plasma in medical treatment. 


Covid-19 Analysis


The COVID-19, which started in China, has now transformed into a pandemic due to the increasing numbers of cases all over the globe. More than two nations are confronting the difficult undertaking of battling this deadly infection. There has been some topsy-turvy dissemination with regards to the increasing number of patients and death rate. The medical services industry, then again, is anticipated to display some acceleration in the market development attributable to the flood in the prerequisites of clinical fundamentals like PPE units, advanced x-beam machines, ventilators, and much more. There has been a critical flood in the examination exercises for creating suitable medications to fix this infection or stop the transmission chain. More than 75 antibody applicants and more than 120 remedial competitors are being thought of and are being tried on different levels. 


Blood plasma derivatives market analysis has witnessed a rise in the demand for the plasma due to the spread of this covid-19 infection. It was observed that this deadly infection could be treated through plasma treatment. 


Regional Market Summary
Global Blood Plasma Derivatives Market Share, by Region, 2018 (%)

Source: World Health Organization (WHO)

Market Dynamics


Drivers


Expanding thrombocytosis rates are considered a significant driver for the development of the Global blood plasma derivatives market. The National Institutes of Health (NIH) and Community for Disease Control (CDC) conduct mindfulness programs for forestalled thrombocytosis and related difficulties. Global Blood Plasma Derivatives Industry was about is relied upon to arrive at US$ 30.5 billion by 2023 at a CAGR of 7.52% during estimated period 2017 to 2023. This driver is effectively driving the growth of the blood plasma derivatives market in the forecasted period. 


Challenges


The singular market affecting variables and changes in the guideline in the market is locally impacting the current and future patterns of blood plasma derivatives market. The information focuses on utilization volumes, creation destinations and volumes, cost of crude materials, import send out examination, value pattern investigation, downstream and upstream worth chain examination, which is a portion of the significant pointers used to handle the market situation for singular nations. Additionally, the presence and accessibility of worldwide brands and their challenges are affecting the growth of the neighborhood and local brands. It also affects local duties, and shipping lanes are thought of while investigating the nation's information. These challenges are restricting the growth of the blood plasma derivatives market. 


Opportunities


Expanding the selection of blood plasma derivatives items, developing an effective populace, and expanding mindfulness about blood and plasma gifts will probably speed up the development of the blood plasma derivatives market in the figure time of 2020-2027. Then again, developing the expense of plasma derivatives-based treatment will also support different freedoms that will prompt the development of the animal blood plasma products and derivatives market in the estimated time frame.


Restraints


A post-usable danger related to plasma derivatives treatment will probably hamper the development of the plasma products and derivatives market in the forecasted time frame.


Cumulative growth Analysis


Blood plasma derivatives have a wide scope of clinical applications. These are utilized in the treatment of different perilous sicknesses. Blood plasma derivatives are gotten from blood givers. Headway and improvement of better strategies for conserving these blood plasma derivatives alongside fresher and created methods for fractionation fuel the development of the Global blood plasma derivatives market. Additionally, rising instances of dangerous sicknesses like hepatitis, HIV, and hemophilia provoke interest and opportunity in the global blood plasma derivatives market. Besides, different government and non-administrative associations' drives to direct and advance blood gift camps have expanded human blood assortment. This is boosting the development of the blood plasma derivatives industry. 


Blood Plasma Derivatives Market Segment Overview


By Type


Based on type, the blood plasma derivatives market is effectively segmented into egg whites, immunoglobulin, factor VIII, factor IX, hyperimmune globulin, and much more. The immunoglobulin section represented the biggest portion of the overall industry and is required to proceed with this pattern all through the estimated period. Then again, the egg whites portion is expected to develop at a huge CAGR of 9.4% during the figure time frame. 


By Application


Based on application, the blood plasma derivatives market is divided into hemophilia, immunodeficiency infections, hypogammaglobulinemia, von Willebrand's Disease (vWD), and different applications. The immunodeficiency illnesses portion represented the biggest part. 


By End-User


Based on end-user, the blood plasma derivatives market is divided into medical centers, clinics, and opposite end users. Medical clinics held the biggest portion of the market, while the center's section is relied upon to enroll the most noteworthy development rate during the estimated time frame. 


By Region


Based on region, the blood plasma derivatives market is segmented as Asia-Pacific, North America, Europe, and LAMEA. North America held the biggest portion of the market, trailed by Europe. Then again, Asia-Pacific is expected to overwhelm the market during the investigation time frame, attributable to the high populace base, expansion in extra cash, and improvement in understanding mindfulness about plasma subsidiaries. In addition, Asia is an enormous mainland and has arisen as a focal point of perilous sicknesses.


Blood Plasma Derivatives Market Regional Analysis 


The blood plasma derivatives market comprises four areas Asia-Pacific North America, Europe, & Middle East, and Africa. North America is mainly segmented into nations, in particular the U.S., Canada & Mexico. Europe market comprises of nations specifically U.K. Italy, France, Germany, Spain and Rest of Europe. The Asia-Pacific market comprises of nations specifically Australia, India, China, Japan, Republic of Korea and Rest of Asia-Pacific and the Middle East and Africa comprises of nations, in particular, United Arab Emirates, Turkey, Saudi Arabia, and Rest of Middle East & Africa. North America is required to be the biggest market for blood plasma derivatives. Expansion in mindfulness with respect to occurrences of thrombocytosis and utilization of plasma derivatives to kill infections causing irresistible illnesses to favor the development of the market around here. Interest for innovative headway in plasma inferred items and broad exploration underway of plasma subordinates start the development of this market in Europe. Asia-Pacific is required to show the quickest development in view of expansion in the pervasiveness of irresistible illnesses and accentuation on safe blood bonding methodology. Nations in Middle East & Africa, for the most part, send out plasma got items from the North American & European nations.


Blood Plasma Derivatives Market Major Market Players


The key players of the Global blood plasma derivatives market:



  • Grigols (Spain)

  • SK Plasma Co., Ltd. (South Korea)

  • Bain Capital, LLC (US)

  • Biotest AG (Germany)

  • Baxter International Inc. (US)

  • Octapharma AG (Switzerland)

  • CSL Limited (Australia)

  • Kedrion S.p.A (Italy)

  • Fusion Healthcare (India)


Recent Developments



  • In March 2020, Grifols, S.A., declared a coordinated effort with US Biomedical Advanced Research Development Authority (BARDA), the Food and Drug Administration (FDA).


Report Overview



  • Market overview highlights the global recognition of blood plasma derivatives market insights overview

  • Analysis based upon COVID 19

  • Explanation upon the Blood Plasma Derivatives Market  Dynamics

  • Value chain analysis for the blood plasma derivatives market size Report.

  • Market segmentation overview

  • The regional analysis of blood plasma derivatives industry overview

  • Competitive landscape analysis

  • Recent Developments of bovine blood plasma derivatives market Forecast


The report highlights the global blood plasma derivatives market development includes its revenue hike's growth potential by the end of the forecast years in 2028.



Report Scope:
Report Attribute/Metric Details
  Market Size

  • 2018: USD 33,590 Million
  • 2027: Significant Value
  •   CAGR   10.1% (2019-2025)
      Base Year   2019
      Forecast Period   2020-2027
      Historical Data   2018
      Forecast Units   Value (USD Million)
      Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
      Segments Covered   Type, Application and End User
      Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
      Key Vendors   Baxter BioScience, Grifols S.A., CSL Behring, ViroPharma, Inc., Talecris Biotherapeutics, Inc., Octapharma, Fusion Healthcare, SK Plasma Co., Ltd., Biotest AG, Green Cross Corporation, and Shire Plc.
      Key Market Opportunities   safety concerns during blood transfusion
      Key Market Drivers

  • rising incidences of infectious diseases
  • growing demand for plasma derivatives to treat life-threatening disorders


  • Frequently Asked Questions (FAQ) :


    The Involved End Users Are Diagnostic Centers, Blood Transfusion Centers, Hospitals & Clinics, And Others.

    The Immune Globulins Segment To Lead The Market.

    The Immunodeficiency Segment Would Head The Market.

    Table of Contents:

    Chapter 1. Report Prologue

    Chapter 2. Market Introduction

    2.1 Definition

    2.2 Scope of the Study

    2.2.1 Research Objective

    2.2.2 Assumptions

    2.2.3 Limitations

    Chapter 3. Research Methodology

    3.1 Overview

    3.2 Primary Research

    3.3 Secondary Research

    3.4 Market Size Estimation

    Chapter 4. Market Dynamics

    4.1 Drivers

    4.2 Restraints

    4.3 Opportunities

    4.4 Challenges

    Chapter 5. Market Factor Analysis

    5.1 Porter’s Five Forces Analysis

    5.1.1 Bargaining Power of Suppliers

    5.1.2 Bargaining Power of Buyers

    5.1.3 Threat of New Entrants

    5.1.4 Threat of Substitutes

    5.1.5 Intensity of Rivalry

    5.2 Value Chain Analysis

    Chapter 6. Global Blood Plasma Derivatives Market, by Type

    6.1 Overview

    6.2 Factor VIII Concentrate

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    6.3 Factor IX Concentrate

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    6.4 Albumin

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    6.5 Immune Globulins

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    6.6 Anti-Thrombin III Concentrate

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    6.7 Fresh Frozen Plasma (FFP)

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    Chapter 7 Global Blood Plasma Derivatives Market, by Application

    7.1 Overview

    7.2 HIV

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    7.3 Hemophilia A

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    7.4 Hemophilia B

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    7.5 Hepatitis B

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    7.6 Hepatitis C

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    7.7 Bleeding disorders

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    7.8 Hypogammaglobulinemia

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    7.9 Immunodeficiency Diseases

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    7.10 Others

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    Chapter 8 Global Blood Plasma Derivatives Market, by End User

    8.1 Overview

    8.2 Hospitals & Clinics

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    8.3 Blood Transfusion Centers

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    8.4 Diagnostic Centers

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    8.5 Others

    Market Estimates & Forecast, by Region, 2020-2027

    Market Estimates & Forecast, by Country, 2020-2027

    Chapter 10. Global Blood Plasma Derivatives Market, by Region

    10.1 Overview

    10.2 Americas

    10.2.1 North America

    10.2.1.1 US

    10.2.1.2 Canada

    10.2.2 Latin America

    10.3 Europe

    10.3.1 Western Europe

    10.3.1.1 Germany

    10.3.1.2 France

    10.3.1.3 Italy

    10.3.1.4 Spain

    10.3.1.5 UK

    10.3.1.6 Rest of Western Europe

    10.3.2 Eastern Europe

    10.4 Asia-Pacific

    10.4.1 Japan

    10.4.2 China

    10.4.3 India

    10.4.4 Australia

    10.4.5 South Korea

    10.4.6 Rest of Asia-Pacific

    10.5 Middle East & Africa

    10.5.1 Middle East

    10.5.2 Africa

    Chapter 11. Company Landscape

    11.1 Overview

    11.2 Competitive Analysis

    Chapter 12. Company Profile

    12.1 Baxter BioScience

    12.1.1 Company Overview

    12.1.2 Product Type Overview

    12.1.3 Financial Overview

    12.1.4 Key Developments

    12.1.5 SWOT Analysis

    12.2 Grifols S.A.

    12.2.1 Company Overview

    12.2.2 Product Type Overview

    12.2.3 Financial Overview

    12.2.4 Key Developments

    12.2.5 SWOT Analysis

    12.3 CSL Behring

    12.3.1 Company Overview

    12.3.2 Product Type Overview

    12.3.3 Financial Overview

    12.3.4 Key Developments

    12.3.5 SWOT Analysis

    12.4 ViroPharma, Inc.

    12.4.1 Company Overview

    12.4.2 Product Type Overview

    12.4.3 Financial Overview

    12.4.4 Key Developments

    12.4.5 SWOT Analysis

    12.5 Talecris Biotherapeutics, Inc.

    12.5.1 Company Overview

    12.5.2 Product Type Overview

    12.5.3 Financial Overview

    12.5.4 Key Developments

    12.5.5 SWOT Analysis

    12.6 Octapharma

    12.6.1 Company Overview

    12.6.2 Product Type Overview

    12.6.3 Financial Overview

    12.6.4 Key Developments

    12.6.5 SWOT Analysis

    12.7 Fusion Healthcare

    12.7.1 Overview

    12.7.2 Product Type Overview

    12.7.3 Financial Overview

    12.7.4 Key Developments

    12.7.5 SWOT Analysis

    12.8 SK Plasma Co., Ltd.

    12.8.1 Overview

    12.8.2 Product Type Overview

    12.8.3 Financial Overview

    12.8.4 Key Developments

    12.8.5 SWOT Analysis

    12.9 Biotest AG

    12.9.1 Overview

    12.9.2 Product Type Overview

    12.9.3 Financial Overview

    12.9.4 Key Developments

    12.9.5 SWOT Analysis

    12.10 Green Cross Corporation

    12.10.1 Overview

    12.10.2 Product Type Overview

    12.10.3 Financial Overview

    12.10.4 Key Developments

    12.10.5 SWOT Analysis

    12.11 Shire Plc

    12.11.1 Overview

    12.11.2 Product Type Overview

    12.11.3 Financial Overview

    12.11.4 Key Developments

    12.11.5 SWOT Analysis

    12.13 Others

    Chapter 13 Appendix

    13.1 References

    13.2 Related Reports

    LIST OF TABLES

    Table 1 Global Blood Plasma Derivatives Market Synopsis, 2020-2027

    Table 2 Global Blood Plasma Derivatives Market Estimates and Forecast, 2020-2027 (USD Million)

    Table 3 Global Blood Plasma Derivatives Market, by Type, 2020-2027 (USD Million)

    Table 4 Global Blood Plasma Derivatives Market, by Applications, 2020-2027 (USD Million)

    Table 5 Global Blood Plasma Derivatives Market, by End users, 2020-2027 (USD Million)

    Table 6 Global Blood Plasma Derivatives Market, by Region, 2020-2027 (USD Million)

    Table 7 North America: Blood Plasma Derivatives Market, by Type, 2020-2027 (USD

    Table 8 North America: Blood Plasma Derivatives Market, by Applications, 2020-2027 (USD

    Table 9 North America: Blood Plasma Derivatives Market, by End users, 2020-2027 (USD

    Table 10 US: Blood Plasma Derivatives Market, by Type, 2020-2027 (USD Million)

    Table 11 US: Blood Plasma Derivatives Market, by Applications, 2020-2027 (USD Million)

    Table 12 US: Blood Plasma Derivatives Market, by End users, 2020-2027 (USD Million)

    Table 13 Canada: Blood Plasma Derivatives Market, by Type, 2020-2027 (USD Million)

    Table 14 Canada: Blood Plasma Derivatives Market, by Applications, 2020-2027 (USD Million)

    Table 15 Canada: Blood Plasma Derivatives Market, by End users, 2020-2027 (USD Million)

    Table 16 Latin America: Blood Plasma Derivatives Market, by Type, 2020-2027 (USD Million)

    Table 17 Latin America: Blood Plasma Derivatives Market, by Applications, 2020-2027 (USD Million)

    Table 18 Latin America: Blood Plasma Derivatives Market, by End users, 2020-2027 (USD Million)

    Table 19 Europe: Blood Plasma Derivatives Market, by Type, 2020-2027 (USD Million)

    Table 20 Europe: Blood Plasma Derivatives Market, by Applications, 2020-2027 (USD Million)

    Table 21 Europe: Blood Plasma Derivatives Market, by End users, 2020-2027 (USD Million)

    Table 22 Western Europe: Blood Plasma Derivatives Market, by Type, 2020-2027 (USD Million)

    Table 23 Western Europe: Blood Plasma Derivatives Market, by Applications, 2020-2027 (USD Million)

    Table 24 Western Europe: Blood Plasma Derivatives Market, by End users, 2020-2027 (USD Million)

    Table 25 Eastern Europe: Blood Plasma Derivatives Market, by Type, 2020-2027 (USD Million)

    Table 26 Eastern Europe: Blood Plasma Derivatives Market, by Applications, 2020-2027 (USD Million)

    Table 27 Eastern Europe: Blood Plasma Derivatives Market, by End users, 2020-2027 (USD Million)

    Table 28 Asia-Pacific: Blood Plasma Derivatives Market, by Type, 2020-2027 (USD Million)

    Table 29 Asia-Pacific: Blood Plasma Derivatives Market, by Applications, 2020-2027 (USD Million)

    Table 30 Asia-Pacific: Blood Plasma Derivatives Market, by End users, 2020-2027 (USD Million)


    Table 31 Middle East & Africa: Blood Plasma Derivatives Market, by Type, 2020-2027 (USD Million)

    Table 32 Middle East & Africa: Blood Plasma Derivatives Market, by Applications, 2020-2027 (USD Million)

    Table 33 Middle East & Africa: Blood Plasma Derivatives Market, by End users, 2020-2027 (USD Million)  

    LIST OF FIGURES

    Figure 1 Research Process

    Figure 2 Market Structure of the Global Blood Plasma Derivatives Market

    Figure 3 Market Dynamics of the Global Blood Plasma Derivatives Market

    Figure 5 Global Blood Plasma Derivatives Market, by Type, 2020-2027 (USD Million)

    Figure 6 Global Blood Plasma Derivatives Market, by Applications, 2020-2027 (USD Million)

    Figure 7 Global Blood Plasma Derivatives Market, by End users, 2020-2027 (USD Million)

    Figure 8 Global Blood Plasma Derivatives Market, by Region, 2020-2027 (USD Million)

    Figure 9 North America: Blood Plasma Derivatives Market Share, by Country, 2020 (%)

    Figure 10 Europe: Blood Plasma Derivatives Market Share, by Region, 2020 (%)

    Figure 11 Western Europe: Blood Plasma Derivatives Market Share, by Country, 2020 (%)

    Figure 12 Asia-Pacific: Blood Plasma Derivatives Market Share, by Country, 2020 (%)

    Figure 13 Middle East & Africa: Blood Plasma Derivatives Market Share, by Country, 2020 (%)

    Figure 14 Global Blood Plasma Derivatives Market: Company Share Analysis, 2020 (%)

    Figure 15 Baxter BioScience: Key Financial Overview

    Figure 16 Baxter BioScience: Segmental Revenue

    Figure 17 Baxter BioScience: Geographic Revenue

    Figure 18 Grifols S.A.: Key Financial Overview

    Figure 19 Grifols S.A.: Segmental Revenue

    Figure 20 Grifols S.A.: Geographic Revenue

    Figure 21 CSL Behring: Key Financial Overview

    Figure 22 CSL Behring: Segmental Revenue

    Figure 23 CSL Behring: Geographic Revenue

    Figure 24 ViroPharma, Inc.: Key Financial Overview

    Figure 25 ViroPharma, Inc.: Segmental Revenue

    Figure 26 ViroPharma, Inc.: Geographic Revenue

    Figure 27 Talecris Biotherapeutics, Inc.: Key Financial Overview

    Figure 28 Talecris Biotherapeutics, Inc.: Segmental Revenue

    Figure 29 Talecris Biotherapeutics, Inc.: Geographic Revenue

    Figure 30 Octapharma: Key Financial Overview

    Figure 31 Octapharma: Segmental Revenue

    Figure 32 Octapharma: Geographic Revenue

    Figure 33 Fusion Healthcare: Key Financial Overview

    Figure 34 Fusion Healthcare: Segmental Revenue

    Figure 35 Fusion Healthcare: Geographic Revenue

    Figure 36 SK Plasma Co., Ltd.: Key Financial Overview

    Figure 37 SK Plasma Co., Ltd.: Segmental Revenue

    Figure 38 SK Plasma Co., Ltd.: Geographic Revenue

    Figure 39 Biotest AG: Key Financial Overview

    Figure 40 Biotest AG: Segmental Revenue

    Figure 41 Biotest AG: Geographic Revenue

    Figure 42 Green Cross Corporation: Key Financial Overview

    Figure 43 Green Cross Corporation: Segmental Revenue

    Figure 44 Green Cross Corporation: Geographic Revenue

    Figure 45 Shire Plc: Key Financial Overview

    Figure 46 Shire Plc: Segmental Revenue

    Figure 47 Shire Plc: Geographic Revenue